Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib pharmacokinetics with OATP1B inhibition by rifampicin
NL-OMON38631Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sorafenib in cancer, renal cell carcinoma (RCC) and thyroid cancer, sponsored by Erasmus MC. Started Aug 2013; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
cancerrenal cell carcinoma (RCC)thyroid cancer
Beyond the preview
Go deeper on NL-OMON38631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38631.